Valvular heart disease refers to structural abnormalities and deformations of the heart valves and subvalvular apparatus caused by various conditions. These abnormalities disrupt intracardiac and systemic hemodynamics, leading to the development of acute or chronic heart failure. While rheumatism used to be the primary cause of mitral stenosis (85%) and less commonly affected the aortic valve (26%), the prevalence of rheumatic valvular disease has significantly decreased. Presently, structural changes associated with atherosclerosis and degenerative processes, often accompanied by the formation of mitral insufficiency and aortic valve stenosis, are more prevalent. Additionally, valvular heart disease can result from infective endocarditis and heart injuries, which is particularly relevant in times of war. As a result, surgical approaches to the treatment of valvular heart disease are evolving.
The National Amosov Institute of Cardiovascular Surgery is at the forefront of constant research, seeking new methods of surgical treatment that align with modern requirements. Our goal is to implement valve-sparing operations and minimally invasive technologies, enhancing both the physical and psychological quality of life for our patients. Currently, up to 40% of mitral regurgitation operations are performed using valve-sparing methods, even in cases of bacterial damage to the valve. This significant advancement greatly improves the overall quality of life for our patients.
By utilizing minimally invasive approaches for the correction of aortic heart defects, we can achieve significant cosmetic improvements while upholding the highest standards of surgical treatment. Our institute has implemented a comprehensive program for the correction of valvular heart disease, incorporating minimally invasive technologies. Our specialists receive training in these techniques at top European clinics. The widespread adoption of thoracoscopic techniques has allowed us to elevate the level of cardiosurgical care, ensuring compliance with modern requirements for valvular heart disease correction.
Since 2013, our institute has pioneered the use of endovascular aortic valve endoprosthesis (TAVI) as a safe alternative to traditional cardiac surgery. This innovative approach has yielded optimal results while significantly reducing the risks associated with surgical interventions.
At the Institute of Cardiovascular Surgery, we are dedicated to providing state-of-the-art treatment for valvular heart disease. Our commitment to research, implementation of advanced techniques, and continuous improvement ensures that our patients receive the highest level of care. Contact us today to learn more about our comprehensive valvular heart disease treatment options and how we can help improve your cardiac health.